Photostability is a critical quality attribute for light-sensitive pharmaceuticals. Exposure to light—especially UV and visible light—can cause photodegradation, impacting potency, safety, and shelf life. Therefore, the selection of packaging materials with effective light barrier properties is essential in stability testing and commercial distribution.
Why Light Protection in Packaging Is Essential
Light-sensitive drugs degrade through oxidation, isomerization, or cleavage when exposed to wavelengths between 300–800 nm. Regulatory agencies require evaluation of photostability during development, as outlined in ICH Q1B. Packaging must serve as a protective barrier to minimize this risk.
- ✓ Prevents loss of active pharmaceutical ingredient (API) potency
- ✓ Minimizes formation of toxic degradation products
- ✓ Maintains physical and visual appearance (e.g., discoloration)
- ✓ Supports accurate stability claims in dossier
Common Light Barrier Packaging Materials
The most effective light barrier materials used in pharmaceutical packaging include:
- Amber Glass: Blocks UV and some visible light; commonly used for liquids
- Opaque HDPE: Suitable for tablets and capsules; moderate light barrier
- Aluminum Foil: Excellent protection for blister packs and sachets
- PVC/PVDC with Colorants: Added pigments enhance UV barrier
- UV-Inhibitor-Coated PET: Used in specialty bottles for oral liquids
Photostability Testing: Link with Packaging
According to ICH Q1B, photostability testing must demonstrate the efficacy of protective packaging. The study involves exposing the drug to light sources and
- Conduct forced degradation on unpackaged product
- Expose product in primary packaging to same conditions
- Compare results to assess packaging protection
If the packaging sufficiently reduces degradation, no further mitigation may be needed. Otherwise, light-resistant packaging or label film must be added.
Quantifying Light Transmission Through Packaging
Packaging specifications often include limits on light transmittance at certain wavelengths:
| Packaging Material | Transmittance at 290–450 nm |
|---|---|
| Amber Glass | < 10% |
| Clear PET | > 85% |
| Opaque HDPE | < 20% |
| Aluminum Blister | < 1% |
Case Study: Switching Packaging to Prevent Photodegradation
A company observed yellow discoloration in a vitamin suspension during accelerated stability testing at 40°C/75% RH. Investigation revealed the clear PET bottle allowed UV exposure, leading to oxidation of light-sensitive ingredients. Switching to amber PET and including an overwrap significantly reduced degradation. This case underscores the need to evaluate packaging early in development.
Best Practices for Light-Sensitive Drug Packaging
- ☑ Perform photostability studies per ICH Q1B
- ☑ Compare exposed vs. unexposed samples in packaging
- ☑ Include UV-transmission data in container specifications
- ☑ Evaluate label films for light resistance if full wrap is used
- ☑ Consider dual-layer systems (e.g., amber bottle + carton)
- ☑ Validate packaging for global climatic zones
Regulatory Requirements and Documentation
Regulators expect the following in the CTD (Common Technical Document):
- Justification of packaging selection for photolabile drugs
- Light-transmission specifications for primary packaging
- Photostability study results in Module 3.2.P.8.3
- Container closure system description in Module 3.2.P.7
- Risk assessment addressing light exposure during distribution
More examples of packaging validation documentation are available at packaging validation.
Checklist: Light Barrier Packaging Assessment
- ☑ Is the API classified as photolabile?
- ☑ Has photostability testing been completed?
- ☑ Does packaging meet transmission specs at 290–450 nm?
- ☑ Is the packaging configuration final or equivalent?
- ☑ Are results included in CTD and supporting files?
Conclusion
Effective light barrier packaging is a cornerstone of photostability in pharmaceutical products. Amber glass, aluminum foil, and UV-inhibited plastics can significantly reduce light-induced degradation, protecting the drug’s quality throughout its shelf life. Through ICH-compliant testing and proper documentation, pharma professionals can ensure regulatory approval and product success.
References:
- ICH Q1B: Photostability Testing of New Drug Substances and Products
- USP : Containers – Performance Testing
- WHO TRS Annex: Packaging for Pharmaceutical Products
- EMA Quality Guidelines: Photostability Testing
- FDA Guidance for Industry: Container Closure Systems